Structure and function of von Willebrand factor: The protein that is deficient and/or abnormal in inherited von Willebrand disease

Blood Coagulation and Fibrinolysis

Volumn 23, Issue 1, 2012, Pages 11-22

  Hassan, Md Imtaiyaz ^a   Saxena, Aditya ^a   Ahmad, Faizan ^a  

^a JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

Author keywords

biomarker; blood clotting; cell adhesion; fibrinogen binding; hemostasis; integrin GPIb; von Willebrand diseases; von Willebrand factor

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 8; COLLAGEN; GLYCOPROTEIN IB; HEPARIN; INTEGRIN; INTEGRIN ALPHA2BBETA3; NONSTEROID ANTIINFLAMMATORY AGENT; SULFATIDE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ALPHA HELIX; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; GENE STRUCTURE; HUMAN; MEGAKARYOCYTE; NONHUMAN; PLATELET TYPE VON WILLEBRAND DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SHEAR STRESS; THROMBOCYTE ADHESION; VON WILLEBRAND DISEASE;

ANIMALS; HUMANS; MODELS, MOLECULAR; PLATELET ADHESIVENESS; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; STRUCTURE-ACTIVITY RELATIONSHIP; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84855190263     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32834cb35d     Document Type: Review

References (141)

1. Hough C, Cuthbert CD, Notley C, Brown C, Hegadorn C, Berber E, et al. Cell type-specific regulation of von Willebrand factor expression by the E4BP4 transcriptional repressor. Blood 2005; 105:1531-1539. (Pubitemid 40223670)
2. Jin SY, Skipwith CG, Zheng XL. Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor. Blood 2010; 115:2300-2310.
3. Fujimura Y, Fukui H, Usami Y, Titani K. Domain structure of human von Willebrand factor, and its modulators involved in the platelet adhesion process in vitro. Rinsho Ketsueki 1991; 32:475-480.
4. Sadler JE. von Willebrand factor assembly and secretion. J Thromb Haemost 2009; 7 (Suppl 1):24-27.
5. Meyer D, Girma JP. von Willebrand factor: Structure and function. Thromb Haemost 1993; 70:99-104. (Pubitemid 23225459)
6. Pimanda J, Hogg P. Control of von Willebrand factor multimer size and implications for disease. Blood Rev 2002; 16:185-192. (Pubitemid 34982975)
7. Reininger AJ. Function of von Willebrand factor in haemostasis and thrombosis. Haemophilia 2008; 14 (Suppl 5):11-26.
8. Reidy MA, Chopek M, Chao S, McDonald T, Schwartz SM. Injury induces increase of von Willebrand factor in rat endothelial cells. Am J Pathol 1989; 134:857-864. (Pubitemid 19111252)
9. Li S, Wang Z, Liao Y, Zhang W, Shi Q, Yan R, et al. The glycoprotein Ibalpha-von Willebrand factor interaction induces platelet apoptosis. J Thromb Haemost 2010; 8:341-350.
10. Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood 1994; 83:3536-3544. (Pubitemid 24175543)
11. Skipwith CG, Cao W, Zheng XL. Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress. J Biol Chem 2010; 285:28596-28603.
12. Fuchs B, Budde U, Schulz A, Kessler CM, Fisseau C, Kannicht C. Flowbased measurements of von Willebrand factor (VWF) function: Binding to collagen and platelet adhesion under physiological shear rate. Thromb Res. 2010; 125:239-245.
13. Zhang Q, Zhou YF, Zhang CZ, Zhang X, Lu C, Springer TA. Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor. Proc Natl Acad Sci U S A 2009; 106:9226-9231.
14. Moroose R, Hoyer LW. von Willebrand factor and platelet function. Annu Rev Med 1986; 37:157-163.
15. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67:395-424. (Pubitemid 28411134)
16. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6:217-246.
17. Millar CM, Brown SA. Oligosaccharide structures of von Willebrand factor and their potential role in von Willebrand disease. Blood Rev 2006; 20:83-92.
18. Mayadas TN, Wagner DD. von Willebrand factor biosynthesis and processing. Ann N Y Acad Sci 1991; 614:153-166.
19. Bonthron DT, Handin RI, Kaufman RJ, Wasley LC, Orr EC, Mitsock LM, et al. Structure of prepro-von Willebrand factor and its expression in heterologous cells. Nature 1986; 324:270-273. (Pubitemid 17180458)
20. Purvis AR, Sadler JE. A covalent oxidoreductase intermediate in propeptide-dependent von Willebrand factor multimerization. J Biol Chem 2004; 279:49982-49988. (Pubitemid 39577807)
21. Verweij CL. Biosynthesis of human von Willebrand factor. Haemostasis 1988; 18:224-245. (Pubitemid 19023118)
22. Yamamoto K, de Waard V, Fearns C, Loskutoff DJ. Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo. Blood 1998; 92:2791-2801. (Pubitemid 28469093)
23. Aird WC, Jahroudi N, Weiler-Guettler H, Rayburn HB, Rosenberg RD. Human von Willebrand factor gene sequences target expression to a subpopulation of endothelial cells in transgenic mice. Proc Natl Acad Sci U S A 1995; 92:4567-4571.
24. Denis CV, Marx I, Badirou I, Pendu R, Christophe O. Mouse models to study von Willebrand factor structure-function relationships in vivo. Hamostaseologie 2009; 29:17-18.
25. Baud'huin M, Duplomb L, Teletchea S, Charrier C, Maillasson M, Fouassier M, et al. Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival. J Biol Chem 2009; 284:31704-31713.
26. Quan L, Ishikawa T, Zhao D, Michiue T, Yoshida C, Chen JH, et al. Immunohistochemistry of von Willebrand factor in the lungs with regard to the cause of death in forensic autopsy. Leg Med (Tokyo) 2009; 11 (Suppl 1):S294-S296.
27. Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer TA. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science 2009; 324:1330-1334.
28. van den Biggelaar M, Bierings R, Storm G, Voorberg J, Mertens K. Requirements for cellular co-trafficking of factor VIII and von Willebrand factor to Weibel-Palade bodies. J Thromb Haemost 2007; 5:2235-2242. (Pubitemid 47617876)
29. Scheja A, Akesson A, Geborek P, Wildt M, Wollheim CB, Wollheim FA, et al. Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma). Arthritis Res 2001; 3:178-182. (Pubitemid 32303434)
30. Hattori R, Hamilton KK, Fugate RD, McEver RP, Sims PJ. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J Biol Chem 1989; 264:7768-7771. (Pubitemid 19137247)
31. Collins P, WilkieM, Razak K, Abbot S, Harley S, Bax C, et al. Cyclosporine and cremaphor modulate von Willebrand factor release from cultured human endothelial cells. Transplantation 1993; 56:1218-1223. (Pubitemid 23348704)
32. Cleator JH, Zhu WQ, Vaughan DE, Hamm HE. Differential regulation of endothelial exocytosis of P-selectin and von Willebrand factor by protease-activated receptors and cAMP. Blood 2006; 107:2736-2744.
33. Vischer UM, Wollheim CB. Epinephrine induces von Willebrand factor release from cultured endothelial cells: Involvement of cyclic AMPdependent signalling in exocytosis. Thromb Haemost 1997; 77:1182-1188. (Pubitemid 27311992)
34. Mannucci PM. Platelet von Willebrand factor in inherited and acquired bleeding disorders. Proc Natl Acad Sci U S A 1995; 92:2428-2432.
35. Favaloro EJ, Thom J, Patterson D, Just S, Dixon T, Koutts J, et al. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: Differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays? Thromb Res 2009; 123:862-868.
36. Johnsen J, Lopez JA. VWF secretion: What's in a name? Blood 2008; 112:926-927.
37. Giblin JP, Hewlett LJ, HannahMJ. Basal secretion of von Willebrand factor from human endothelial cells. Blood 2008; 112:957-964.
38. Ginsburg D, Handin RI, Bonthron DT, Donlon TA, Bruns GA, Latt SA, et al. Human von Willebrand factor (vWF): Isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985; 228:1401-1406. (Pubitemid 15041316)
39. Mancuso DJ, Tuley EA, Westfield LA, Worrall NK, Shelton-Inloes BB, Sorace JM, et al. Structure of the gene for human von Willebrand factor. J Biol Chem 1989; 264:19514-19527. (Pubitemid 20008053)
40. Collins CJ, Underdahl JP, Levene RB, Ravera CP, Morin MJ, Dombalagian MJ, et al. Molecular cloning of the human gene for von Willebrand factor and identification of the transcription initiation site. Proc Natl Acad Sci U S A 1987; 84:4393-4397. (Pubitemid 17097840)
41. Ruggeri ZM, Ware J. von Willebrand factor. FASEB J 1993; 7:308-316. (Pubitemid 23067781)
42. Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 1986; 46:185-190. (Pubitemid 16031685)
43. Chen Q, Zhang Y, Johnson DM, Goetinck PF. Assembly of a novel cartilage matrix protein filamentous network: Molecular basis of differential requirement of von Willebrand factor A domains. Mol Biol Cell 1999; 10:2149-2162. (Pubitemid 29343125)
44. Carew JA, Quinn SM, Stoddart JH, Lynch DC. O-Linked carbohydrate of recombinant von Willebrand factor influences ristocetin-induced binding to platelet glycoprotein 1b. J Clin Invest 1992; 90:2258-2267. (Pubitemid 23010040)
45. Carew JA, Browning PJ, Lynch DC. Sulfation of von Willebrand factor. Blood 1990; 76:2530-2539.
46. van Schooten CJ, Denis CV, Lisman T, Eikenboom JC, Leebeek FW, Goudemand J, et al. Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood 2007; 109:2430-2437. (Pubitemid 46425885)
47. Rosenberg JB, Haberichter SL, Jozwiak MA, Vokac EA, Kroner PA, Fahs SA, et al. The role of the D1 domain of the von Willebrand factor propeptide in multimerization of VWF. Blood 2002; 100:1699-1706. (Pubitemid 34925147)
48. Tjernberg P, Vos HL, Castaman G, Bertina RM, Eikenboom JC. Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues. J Thromb Haemost 2004; 2:257-265. (Pubitemid 40186039)
49. Hommais A, Stepanian A, Fressinaud E, Mazurier C, Pouymayou K, Meyer D, et al. Impaired dimerization of von Willebrand factor subunit due to mutation A2801D in the CK domain results in a recessive type 2A subtype IID von Willebrand disease. Thromb Haemost 2006; 95:776-781.
50. Dong Z, Thoma RS, Crimmins DL, McCourt DW, Tuley EA, Sadler JE. Disulfide bonds required to assemble functional von Willebrand factor multimers. J Biol Chem 1994; 269:6753-6758. (Pubitemid 24191065)
51. Voorberg J, Fontijn R, van Mourik JA, Pannekoek H. Domains involved in multimer assembly of von Willebrand factor (vWF): Multimerization is independent of dimerization. EMBO J 1990; 9:797-803.
52. Gaucher C, Dieval J, Mazurier C. Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease. Blood 1994; 84:1024-1030. (Pubitemid 24245864)
53. Zanardelli S, Crawley JT, Chion CK, Lam JK, Preston RJ, Lane DA. ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem 2006; 281:1555-1563.
54. Zanardelli S, Chion AC, Groot E, Lenting PJ, McKinnon TA, Laffan MA, et al. A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood 2009; 114:2819-2828.
55. Emsley J, Cruz M, Handin R, Liddington R. Crystal structure of the von Willebrand factor A1 domain and implications for the binding of platelet glycoprotein Ib. J Biol Chem 1998; 273:10396-10401. (Pubitemid 28227648)
56. Celikel R, Madhusudan, Varughese KI, ShimaM, Yoshioka A, Ware J, et al. Crystal structure of NMC-4 fab antivon Willebrand factor A1 domain. Blood Cells Mol Dis. 1997; 23:123-134. (Pubitemid 27310964)
57. Celikel R, Varughese KI, Madhusudan, Yoshioka A, Ware J, Ruggeri ZM. Crystal structure of the von Willebrand factor A1 domain in complex with the function blocking NMC-4 Fab. Nat Struct Biol. 1998; 5:189-194. (Pubitemid 28113749)
58. Cruz MA, Diacovo TG, Emsley J, Liddington R, Handin RI. Mapping the glycoprotein Ib-binding site in the von Willebrand factor A1 domain. J Biol Chem 2000; 275:19098-19105. (Pubitemid 30422878)
59. Huizinga EG, Tsuji S, Romijn RA, Schiphorst ME, de Groot PG, Sixma JJ, et al. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science 2002; 297:1176-1179. (Pubitemid 36196734)
60. Maita N, Nishio K, Nishimoto E, Matsui T, Shikamoto Y, Morita T, et al. Crystal structure of von Willebrand factor A1 domain complexed with snake venom, bitiscetin: Insight into glycoprotein Ibalpha binding mechanism induced by snake venom proteins. J Biol Chem 2003; 278:37777-37781. (Pubitemid 37175304)
61. Bienkowska J, Cruz M, Atiemo A, Handin R, Liddington R. The von Willebrand factor A3 domain does not contain a metal ion-dependent adhesion site motif. J Biol Chem 1997; 272:25162-25167. (Pubitemid 27415701)
62. Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sci U S A 1992; 89:3531-3535.
63. Matsushita T, Sadler JE. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-toalanine scanning mutagenesis of the A1 domain of human von Willebrand factor. J Biol Chem 1995; 270:13406-13414.
64. Lacy DB, Wigelsworth DJ, Scobie HM, Young JA, Collier RJ. Crystal structure of the von Willebrand factor A domain of human capillary morphogenesis protein 2: An anthrax toxin receptor. Proc Natl Acad Sci U S A 2004; 101:6367-6372. (Pubitemid 38585980)
65. Hirotsu S, Mizuno H, Fukuda K, Qi MC, Matsui T, Hamako J, et al. Crystal structure of bitiscetin, a von Willebrand factor-dependent platelet aggregation inducer. Biochemistry 2001; 40:13592-13597. (Pubitemid 33130786)
66. Gao W, Anderson PJ, Majerus EM, Tuley EA, Sadler JE. Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease. Proc Natl Acad Sci U S A 2006; 103:19099-19104. (Pubitemid 350002834)
67. Huizinga EG, Martijn van der Plas R, Kroon J, Sixma JJ, Gros P. Crystal structure of the A3 domain of human von Willebrand factor: Implications for collagen binding. Structure 1997; 5:1147-1156.
68. Nishida N, Miyazawa M, Sumikawa H, Sakakura M, Shimba N, Takahashi H, et al. Backbone 1H, 13C, and 15N resonance assignments of the von Willebrand factor A3 domain. J Biomol NMR 2002; 24:357-358. (Pubitemid 36157541)
69. Riddell AF, Gomez K, Millar CM, Mellars G, Gill S, Brown SA, et al. Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor. Blood 2009; 114:3489-3496.
70. Romijn RA, Westein E, Bouma B, Schiphorst ME, Sixma JJ, Lenting PJ, et al. Mapping the collagen-binding site in the von Willebrand factor-A3 domain. J Biol Chem 2003; 278:15035-15039. (Pubitemid 36799836)
71. Fischer BE, Schlokat U, Reiter M, Mundt W, Dorner F. Biochemical and functional characterization of recombinant von Willebrand factor produced on a large scale. Cell Mol Life Sci 1997; 53:943-950. (Pubitemid 28021509)
72. Park SW, Choi SY. Long-term expression of von Willebrand Factor by a VSV-G pseudotyped lentivirus enhances the functional activity of secreted B-Domain-deleted Coagulation Factor VIII. Mol Cells 2007; 24:125-131. (Pubitemid 47554800)
73. Franchini M, Lippi G. The role of von Willebrand factor in hemorrhagic and thrombotic disorders. Crit Rev Clin Lab Sci 2007; 44:115-149.
74. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, et al. The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 2011; 39:D561-568.
75. Sadler JE. Biomedicine. Contact - how platelets touch von Willebrand factor. Science 2002; 297:1128-1129.
76. Laduca FM, Bell WR, Bettigole RE. Platelet-collagen adhesion enhances platelet aggregation induced by binding of VWF to platelets. Am J Physiol 1987; 253:H1208-1214.
77. Lankhof H, Damas C, Schiphorst ME, Ijsseldijk MJ, Bracke M, Furlan M, et al. Recombinant vWF type 2A mutants R834Q and R834W show a defect in mediating platelet adhesion to collagen, independent of enhanced sensitivity to a plasma protease. Thromb Haemost 1999; 81:976-983. (Pubitemid 29312718)
78. Dejana E, Lampugnani MG, Giorgi M, Gaboli M, Federici AB, Ruggeri ZM, et al. Von Willebrand factor promotes endothelial cell adhesion via an Arg-Gly-Asp-dependent mechanism. J Cell Biol 1989; 109:367-375. (Pubitemid 19180143)
79. Ruggeri ZM. Structure and function of von Willebrand factor: Relationship to von Willebrand's disease. Mayo Clin Proc 1991; 66:847-861.
80. Morales LD, Martin C, Cruz MA. The interaction of von Willebrand factor- A1 domain with collagen: Mutation G1324S (type 2M von Willebrand disease) impairs the conformational change in A1 domain induced by collagen. J Thromb Haemost 2006; 4:417-425.
81. Kang I, Raghavachari M, Hofmann CM, Marchant RE. Surface-dependent expression in the platelet GPIb binding domain within human von Willebrand factor studied by atomic force microscopy. Thromb Res 2007; 119:731-740. (Pubitemid 46442868)
82. Dayananda KM, Singh I, Mondal N, Neelamegham S. Von Willebrand Factor self-association on platelet GpIb{alpha} under hydrodynamic shear: Effect on shear-induced platelet activation. Blood 2010; 116:3990-3998.
83. Bonnefoy A, Vermylen J, Hoylaerts MF. Inhibition of von Willebrand factor- GPIb/IX/V interactions as a strategy to prevent arterial thrombosis. Expert Rev Cardiovasc Ther 2003; 1:257-269.
84. Shimizu A, Matsushita T, Kondo T, Inden Y, Kojima T, Saito H, et al. Identification of the amino acid residues of the platelet glycoprotein Ib (GPIb) essential for the von Willebrand factor binding by clustered charged-to-alanine scanning mutagenesis. J Biol Chem 2004; 279:16285-16294. (Pubitemid 38509323)
85. Leyte A, van Schijndel HB, Niehrs C, Huttner WB, Verbeet MP, Mertens K, et al. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 1991; 266:740-746. (Pubitemid 21907177)
86. Scott JP, Montgomery RR, Retzinger GS. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factordependent agglutination of platelets. J Biol Chem 1991; 266:8149-8155. (Pubitemid 21906489)
87. Gardiner EE, Arthur JF, Shen Y, Karunakaran D, Moore LA, Am Esch JS 2nd, et al. GPIbalpha-selective activation of platelets induces platelet signaling events comparable to GPVI activation events. Platelets 2010; 21:244-252.
88. Mekrache M, Bachelot-Loza C, Ajzenberg N, Saci A, Legendre P, Baruch D. Activation of pp125FAK by type 2B recombinant von Willebrand factor binding to platelet GPIb at a high shear rate occurs independently of alpha IIb beta 3 engagement. Blood 2003; 101:4363-4371. (Pubitemid 36857800)
89. Brill A, Fuchs TA, Chauhan AK, Yang JJ, De Meyer SF, Kollnberger M, et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 2011; 117:1400-1407.
90. D'Souza SE, Ginsberg MH, Plow EF. Arginyl-glycyl-aspartic acid (RGD): A cell adhesion motif. Trends Biochem Sci 1991; 16:246-250. (Pubitemid 121004445)
91. Aoki T, Tomiyama Y, Honda S, Mihara K, Yamanaka T, Okubo M, et al. Association of the antagonism of von Willebrand factor but not fibrinogen by platelet alphaIIbbeta3 antagonists with prolongation of bleeding time. J Thromb Haemost 2005; 3:2307-2314. (Pubitemid 41727211)
92. Wu YP, de Groot PG, Sixma JJ. Shear-stress-induced detachment of blood platelets from various surfaces. Arterioscler Thromb Vasc Biol 1997; 17:3202-3207. (Pubitemid 28016078)
93. Auton M, Sedlak E, Marek J, Wu T, Zhu C, Cruz MA. Changes in thermodynamic stability of von Willebrand factor differentially affect the force-dependent binding to platelet GPIbalpha. Biophys J 2009; 97:618-627.
94. Vettore S, Scandellari R,Moro S, Lombardi AM, Scapin M, Randi ML, et al. Novel point mutation in a leucine-rich repeat of the GPIbalpha chain of the platelet von Willebrand factor receptor, GPIb/IX/V, resulting in an inherited dominant form of Bernard-Soulier syndrome affecting two unrelated families: The N41H variant. Haematologica 2008; 93:1743-1747.
95. Keuren JF, Baruch D, Legendre P, Denis CV, Lenting PJ, Girma JP, et al. von Willebrand factor C1C2 domain is involved in platelet adhesion to polymerized fibrin at high shear rate. Blood 2004; 103:1741-1746. (Pubitemid 38268967)
96. Bergmeier W, Piffath CL, Goerge T, Cifuni SM, Ruggeri ZM, Ware J, et al. The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci U S A 2006; 103:16900-16905. (Pubitemid 44737350)
97. Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 1987; 262:8443-8446.
98. Leyte A, Verbeet MP, Brodniewicz-Proba T, Van Mourik JA, Mertens K. The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII. Biochem J 1989; 257:679-683. (Pubitemid 19050122)
99. Hilbert L, Jorieux S, Proulle V, Favier R, Goudemand J, Parquet A, et al. Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII-binding capacity. Br J Haematol 2003; 120:627-632. (Pubitemid 36255863)
100. Roberts DD, Williams SB, Gralnick HR, Ginsburg V. von Willebrand factor binds specifically to sulfated glycolipids. J Biol Chem 1986; 261:3306-3309. (Pubitemid 17204945)
101. Borthakur G, Cruz MA, Dong JF, McIntire L, Li F, Lopez JA, et al. Sulfatides inhibit platelet adhesion to von Willebrand factor in flowing blood. J Thromb Haemost 2003; 1:1288-1295.
102. Christophe O, Obert B, Meyer D, Girma JP. The binding domain of von Willebrand factor to sulfatides is distinct from those interacting with glycoprotein Ib, heparin, and collagen and resides between amino acid residues Leu 512 and Lys 673. Blood 1991; 78:2310-2317.
103. Nakayama T, Matsushita T, Yamamoto K, Mutsuga N, Kojima T, Katsumi A, et al. Identification of amino acid residues responsible for von Willebrand factor binding to sulfatide by charged-to-alanine-scanning mutagenesis. Int J Hematol 2008; 87:363-370.
104. Sobel M, McNeill PM, Carlson PL, Kermode JC, Adelman B, Conroy R, et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991; 87:1787-1793.
105. Sobel M, Soler DF, Kermode JC, Harris RB. Localization and characterization of a heparin binding domain peptide of human von Willebrand factor. J Biol Chem 1992; 267:8857-8862.
106. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69:454-459. (Pubitemid 17022013)
107. Ginsburg D, Bowie EJ. Molecular genetics of von Willebrand disease. Blood 1992; 79:2507-2519.
108. Victor M, Rugeri L, Nougier C, Meunier S, Fretigny M, Negrier C, et al. Contribution of genetical analysis for diagnosis of von Willebrand's disease type 2B. Haemophilia 2009; 15:610-612.
109. Kreuz W. von Willebrand's disease: From discovery to therapy - milestones in the last 25 years. Haemophilia 2008; 14 (Suppl 5):1-2.
110. Rugeri L, Beguin S, Hemker C, Bordet JC, Fleury R, Chatard B, et al. Thrombin-generating capacity in patients with von Willebrand's disease. Haematologica 2007; 92:1639-1646. (Pubitemid 350248243)
111. Pergolizzi RG, Jin G, Chan D, Pierre L, Bussel J, Ferris B, et al. Correction of a murine model of von Willebrand disease by gene transfer. Blood 2006; 108:862-869. (Pubitemid 44154618)
112. Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, et al. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease. Clin Appl Thromb Hemost 2006; 12:397-420. (Pubitemid 44359238)
113. Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev 2010; 24:123-134.
114. Sadler JE. Low von Willebrand factor: Sometimes a risk factor and sometimes a disease. Hematol Am Soc Hematol Educ Program 2009:106-112.
115. Haberichter SL, Castaman G, Budde U, Peake I,Goodeve A, Rodeghiero F, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008; 111:4979-4985.
116. Othman M, Chirinian Y, Brown C, Notley C, Hickson N, Hampshire D, et al. Functional characterization of a 13 bp deletion (c.-1522- 1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. Blood 2010; 116:3645-3652.
117. Kujovich JL. von Willebrand's disease and menorrhagia: Prevalence, diagnosis, and management. Am J Hematol 2005; 79:220-228. (Pubitemid 40967079)
118. Casonato A, Gallinaro L, Cattini MG, Pontara E, Padrini R, Bertomoro A, et al. Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia. Haematologica 2010; 95:1366-1372.
119. Federici AB, Berntorp E, Lee CA. The 80th anniversary of von Willebrand's disease: History, management and research. Haemophilia 2006; 12:563-572. (Pubitemid 44697527)
120. Bernardi F, Casonato A, Marchetti G, Gemmati D, Bizzaro N, Pontara E, et al. Two novel mutations (Pro864His, Val867Glu) causing type 2A von Willebrand disease and affecting a single restriction site in exon 28. Br J Haematol 1998; 103:885-887. (Pubitemid 28545335)
121. Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 1980; 302:1047-1051. (Pubitemid 10123105)
122. Jackson SC, Sinclair GD, Cloutier S, Duan Z, Rand ML, Poon MC. The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316 M mutation. Blood 2009; 113:3348-3351.
123. Federici AB, Mannucci PM, Castaman G, Baronciani L, Bucciarelli P, Canciani MT, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: A cohort study of 67 patients. Blood 2009; 113:526-534.
124. Hermans C, Batlle J. Autosomal dominant von Willebrand disease type 2 M. Acta Haematol 2009; 121:139-144.
125. Hillery CA, Mancuso DJ, Evan Sadler J, Ponder JW, Jozwiak MA, Christopherson PA, et al. Type 2 M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin - but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood 1998; 91:1572-1581. (Pubitemid 28110321)
126. Allen S, Abuzenadah AM, Blagg JL, Hinks J, Nesbitt IM, Goodeve AC, et al. Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood 2000; 95:2000-2007. (Pubitemid 30151638)
127. Mazurier C, Goudemand J, Hilbert L, Caron C, Fressinaud E, Meyer D. Type 2N von Willebrand disease: Clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol 2001; 14:337-347. (Pubitemid 32677083)
128. Castaman G, Rodeghiero F, Tosetto A, Cappelletti A, Baudo F, Eikenboom JC, et al. Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: An international, multicenter study. J Thromb Haemost 2006; 4:2164-2169. (Pubitemid 44400291)
129. Federici AB. Clinical diagnosis of von Willebrand disease. Haemophilia 2004; 10 (Suppl 4):169-176. (Pubitemid 40045438)
130. Othman M, Hamilton A. Platelet-type von Willebrand disease: Results of a worldwide survey from the Canadian PT-VWD project. Acta Haematol 2010; 123:126-128.
131. Favaloro EJ, Patterson D, Denholm A, Mead S, Gilbert A, Collins A, et al. Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis. Br J Haematol 2007; 139:623-626. (Pubitemid 350043816)
132. Othman M, Notley C, Lavender FL, White H, Byrne CD, Lillicrap D, et al. Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease. Blood 2005; 105:4330-4336. (Pubitemid 40720779)
133. Murata M, Russell SR, Ruggeri ZM, Ware J. Expression of the phenotypic abnormality of platelet-type von Willebrand disease in a recombinant glycoprotein Ib alpha fragment. J Clin Invest 1993; 91:2133-2137. (Pubitemid 23141488)
134. Turecek PL, Siekmann J, Schwarz HP. Comparative study on collagenbinding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor. Semin Thromb Hemost 2002; 28:149-160. (Pubitemid 34439205)
135. Chen D, Daigh CA, Hendricksen JI, Pruthi RK, Nichols WL, Heit JA, et al. A highly-sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry. J Thromb Haemost 2008; 6:323-330.
136. Favaloro EJ. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007; 33:727-744. (Pubitemid 351158442)
137. Baronciani L, Federici AB, Cozzi G, Canciani MT, Mannucci PM. von Willebrand factor collagen binding assay in von Willebrand disease type 2A, 2B, and 2M. J Thromb Haemost 2006; 4:2088-2090. (Pubitemid 44226803)
138. Hayata K, Nakayama T, Matsushita T, Sakano K. A new binding assay of von Willebrand factor and glycoprotein Ib using solid-phase biotinylated platelets. J Pharmacol Sci 2008; 108:217-221.
139. Zhukov O, Popov J, Ramos R, Vause C, Ruden S, Sferruzza A, et al. Measurement of von Willebrand factor-FVIII binding activity in patients with suspected von Willebrand disease type 2N: Application of an ELISAbased assay in a reference laboratory. Haemophilia 2009; 15:788-796.
140. Hillarp A, Stadler M, Haderer C, Weinberger J, Kessler CM, Romisch J. Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay using a novel automated assay protocol. J Thromb Haemost 2010; 8:2216-2223.
141. Favaloro EJ, Mohammed S, McDonald J. Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay. J Thromb Haemost 2010; 8:2842-2844.